Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
NCT ID: NCT02880293
Last Updated: 2024-12-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
44 participants
INTERVENTIONAL
2016-08-23
2023-11-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients will undergo donor/recipient bone marrow
All patients will undergo haploidentical, allogeneic hematopoietic cell transplantation. Conditioning will consist of fludarabine, melphalan, and thiotepa. Graft versus host disease prophylaxis will be with post-transplant cyclophosphamide in addition to standard tacrolimus and mycophenolate mofetil. Donors will undergo HLA and KIR geno- and allotyping to determine the best donor.
melphalan
melphalan (140 mg/m2 IV on day -7)
fludarabine
fludarabine (40 mg/m2/d on days -5 through -2)
thiotepa
thiotepa (5 mg/kg IV on day -67)
Cyclophosphamide
cyclophosphamide (50 mg/kg IV on day +3 and +4)
Mesna
Mycophenolate Mofetil
(15 mg/kg PO/IV TID)
Filgrastim
Tacrolimus
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
melphalan
melphalan (140 mg/m2 IV on day -7)
fludarabine
fludarabine (40 mg/m2/d on days -5 through -2)
thiotepa
thiotepa (5 mg/kg IV on day -67)
Cyclophosphamide
cyclophosphamide (50 mg/kg IV on day +3 and +4)
Mesna
Mycophenolate Mofetil
(15 mg/kg PO/IV TID)
Filgrastim
Tacrolimus
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute lymphoid leukemia (ALL) in first complete remission (CR1) with high riskfor relapse including:
* t(9;22) or detected BCR-ABL1 translocation by genomic methodologies
* BCR-ABL1-Like B-ALL \[54\] including mutations of IKZF1 or CRLF2
* Translocations or mutations involving 11q23 (MLL) gene.
* Hypodiploid karyotype
* Deletion of 9p
* Loss of 17p or TP53 mutation
* T-lymphocyte lineage antigen expression (T-ALL)
* CNS or other extramedullary involvement
* WBC count \>/= 100,000 cells/μL at diagnosis
* Relapsed ALL, biphenotypic/bilineal leukemia, or AML with \</= 10% blasts in the bone marrow prior to transplantation
* Acute biphenotypic or bilineal leukemia in first or greater complete remission.
* Acute myeloid leukemia (AML) in CR1 with intermediate or high risk features including:
* Cytogeneic abnormalities associated with myelodysplatic syndrome including abnormalities of chromosome 5 or 7
* History of anti-neoplastic therapy (radiation or chemotherapy)
* Extramedullary involvement
* WBC count \>/= 100,00 cells/ul at diagnosis
* Rearrangements or mutations of 11q23 (MLL)
* Abnormalities of chromosome 3
* TP53 mutation or loss of 17p
* Complex or monosomal karyotype
* Normal karyotype with mutations of FLT3, RUNX1, or ASXL1
* Myleodysplastic syndrome, myeloproliferative neoplasms, or MDS/MPN overlap syndrome with:
* International prognostic scoring system risk score of INT-2 or high risk at the time of transplant evaluation
* Any risk category if life-threatening cytopenia exists
* Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype
* Myelofibrosis with DIPSS scores of INT-2 or high risk or any risk category if life threatening cytopenias are present
* Chronic myelomonocytic leukemia (CMML)
* Chronic myeloid leukemia (CML) who have failed or are intolerant to BCR-ABL tyrosine kinase inhibitors
* CML with BCR-ABL mutation consistent with poor response to tyrosine kinase inhibition (e.g. T351 l mutation)
* CML with accelerated or blast phase with \<20% blasts after therapy
* Hodgkin lymphoma:
* Relapsed disease with progression after autologous bone marrow transplant or are ineligible for this procedure
* Responding to therapy prior to enrollment
* Non-Hodgkin lymphoma:
* Responding to therapy prior to enrollment
* Progression after autologous bone marrow transplant or are ineligible for this procedure
* Chronic lymphocytic leukemia with high risk disease as defined by the EBMT consensus criteria
* Patients aged 18 through 69 years old are eligible
* Patients aged 70-75 with HCT-CI of 0-1 are eligible
* High risk hematologic malignancies
* Patients must have Karnofsky performance status \>/= 70%
* Cardiac left ventricular ejection fraction \>/= 50% at rest
* Total bilirubin \</= 2 mg/dL, except for patients with Gilbert's syndrome
* AST and ALT \</= 5x ULN unless thought to be disease related
* Estimated or measured creatinine clearance \> 50 mL/min
* Hemoglobin adjusted pulmonary DLCO \>/= 50% of predicted, if Hgb is within normal range, unadjusted DLCO must be \>/= 50%
Exclusion Criteria
* Female patients who are pregnant or breast-feeding
* Persons with an infection that is not responding to antimicrobial therapy
* Persons who are seropositive for HIV.
* Persons with uncontrolled central nervous system malignancy •Persons who do not meet the age and organ function criteria specified above Presence of psychiatric or neurologic disease, or lack of social support that limits the patient's ability to comply with the treatment protocol including supportive care, follow-up, and research tests.
* Prior diagnosis of non-hematologic malignancy within 5 years of planned protocol therapy EXCEPT:
* Diagnosis of breast ductal carcinoma in situ treated with curative intent
* Diagnosis of prostate adenocarcinoma with Gleasons score \</= 6 treated with curative intent
* Non-melanomatous skin cancer
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian Shaffer, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-1237
Identifier Type: -
Identifier Source: org_study_id